BioHarvest Sciences (NASDAQ:BHST) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Key Points

• BioHarvest reported EPS of ($0.10), beating consensus by $0.01, with Q4 revenue of $9.1M (+25% YoY), full‑year revenue of $34.5M (+37%), Q4 adjusted EBITDA of $0.5M, improved gross margins (~59%) and year‑end cash of $23M.
• The VINIA direct‑to‑consumer business surpassed 85,000 active users and is the #1 U.S. resveratrol brand, while the CDMO unit completed stage one of a first‑ever stable cell culture, retains 20% of resulting compositions, has four third‑party programs and expects external CDMO revenue toward $4–6M in 2026.
• Management is ramping investment in CDMO, manufacturing and marketing—which will make near‑term results lumpy and raise operating expenses—to accelerate growth in 2027–2028, as shares trade around $4.37 amid mixed analyst ratings and recent institutional buying.

BioHarvest Sciences (NASDAQ:BHST - Get Free Report) announced its earnings results on Tuesday. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.01, Zacks reports. The business had revenue of $9.07 million for the quarter, compared to analyst estimates of $9.24 million. BioHarvest Sciences had a negative net margin of 36.33% and a negative return on equity of 1,041.86%.

Here are the key takeaways from BioHarvest Sciences' conference call:

• Q4 revenue was $9.1M (+25% YoY) and full‑year revenue was $34.5M (+37% YoY), with Q4 adjusted EBITDA of $0.5M, improved gross margins (~59%), and year‑end cash of $23M, reflecting materially stronger profitability and liquidity.
• The VINIA direct‑to‑consumer business exceeded 85,000 active users, earned the #1 U.S. resveratrol brand position, and the new VINIA Blood Flow Hydration launch is showing strong early traction (15% of new‑customer revenue and ~4.8–4.9 ratings), prompting a shift to digital marketing to reach younger cohorts.
• The CDMO unit hit a major technical milestone by completing stage one for a rare fragrance plant (first‑ever stable cell culture), retains 20% ownership of resulting compositions, has four active third‑party programs (including Tate & Lyle and Saffron Tech), and expects external CDMO revenue to rise toward $4–6M in 2026.
• Management is investing heavily in CDMO and manufacturing capabilities (AI, process engineering, elicitation center) and increasing marketing spend, which will make near‑term results lumpy and raise operating expenses but is presented as a deliberate trade‑off to accelerate growth in 2027–2028.

BioHarvest Sciences Price Performance

Shares of NASDAQ BHST traded up $0.03 during mid-day trading on Wednesday, reaching $4.37. The company's stock had a trading volume of 4,311 shares, compared to its average volume of 26,138. The stock has a 50-day moving average of $4.61 and a two-hundred day moving average of $6.65. The stock has a market capitalization of $85.68 million, a P/E ratio of -6.49 and a beta of 1.14. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.02 and a current ratio of 1.35. BioHarvest Sciences has a 1-year low of $4.10 and a 1-year high of $12.80.

Institutional Trading of BioHarvest Sciences

Several large investors have recently bought and sold shares of the business. Alyeska Investment Group L.P. acquired a new stake in BioHarvest Sciences in the 4th quarter valued at about $3,929,000. Evercore Wealth Management LLC purchased a new stake in shares of BioHarvest Sciences in the fourth quarter valued at approximately $724,000. Osaic Holdings Inc. increased its holdings in shares of BioHarvest Sciences by 5,510.4% in the fourth quarter. Osaic Holdings Inc. now owns 35,233 shares of the company's stock valued at $183,000 after purchasing an additional 34,605 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of BioHarvest Sciences in the fourth quarter valued at approximately $173,000. Finally, Jane Street Group LLC purchased a new position in BioHarvest Sciences during the fourth quarter worth approximately $145,000.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on BHST. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of BioHarvest Sciences in a research note on Friday. Roth Mkm began coverage on BioHarvest Sciences in a report on Thursday, February 19th. They set a "buy" rating and a $10.00 target price for the company. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $13.00.

BioHarvest Sciences Company Profile

BioHarvest Sciences Inc is a biotechnology company that specializes in the development and commercialization of plant-based active ingredients through proprietary cell-culture technology. By growing undifferentiated plant cells in controlled bioreactor environments, the company aims to produce full-spectrum phytonutrients and botanical compounds that are difficult to obtain through traditional farming methods. This approach is designed to deliver consistent, high-purity extracts with reduced environmental impact and supply-chain variability.

The company's product portfolio focuses on applications across the cosmeceutical, nutraceutical and health-and-wellness markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.